Laboratory of Molecular Biology, Istituto di Ricerche Farmacologiche Mario Negri, 20156 Milano, Italy.
J Biol Chem. 2011 Feb 4;286(5):4027-42. doi: 10.1074/jbc.M110.184994. Epub 2010 Dec 3.
Retinoids are promising agents for the treatment/prevention of breast carcinoma. We examined the role of microRNAs in mediating the effects of all-trans-retinoic acid (ATRA), which suppresses the proliferation of estrogen receptor-positive (ERα(+)) breast carcinoma cells, such as MCF-7, but not estrogen receptor-negative cells, such as MDA-MB-231. We found that pro-oncogenic miR-21 is selectively induced by ATRA in ERα(+) cells. Induction of miR-21 counteracts the anti-proliferative action of ATRA but has the potentially beneficial effect of reducing cell motility. In ERα(+) cells, retinoid-dependent induction of miR-21 is due to increased transcription of the MIR21 gene via ligand-dependent activation of the nuclear retinoid receptor, RARα. RARα is part of the transcription complex present in the 5'-flanking region of the MIR21 gene. The receptor binds to two functional retinoic acid-responsive elements mapping upstream of the transcription initiation site. Silencing of miR-21 enhances ATRA-dependent growth inhibition and senescence while reverting suppression of cell motility afforded by the retinoid. Up-regulation of miR-21 results in retinoid-dependent inhibition of the established target, maspin. Knockdown and overexpression of maspin in MCF-7 cells indicates that the protein is involved in ATRA-induced growth inhibition and contributes to the ATRA-dependent anti-motility responses. Integration between whole genome analysis of genes differentially regulated by ATRA in MCF-7 and MDA-MB-231 cells, prediction of miR-21 regulated genes, and functional studies led to the identification of three novel direct miR-21 targets: the pro-inflammatory cytokine IL1B, the adhesion molecule ICAM-1 and PLAT, the tissue-type plasminogen activator. Evidence for ICAM-1 involvement in retinoid-dependent inhibition of MCF-7 cell motility is provided.
视黄酸是治疗/预防乳腺癌的有前途的药物。我们研究了 microRNAs 在介导全反式视黄酸(ATRA)作用中的作用,ATRA 抑制雌激素受体阳性(ERα(+))乳腺癌细胞如 MCF-7 的增殖,但不抑制雌激素受体阴性细胞如 MDA-MB-231。我们发现,促癌 microRNA-21 被 ATRA 在 ERα(+)细胞中选择性诱导。miR-21 的诱导抵消了 ATRA 的抗增殖作用,但具有降低细胞迁移的潜在有益作用。在 ERα(+)细胞中,视黄酸依赖性 miR-21 的诱导归因于 MIR21 基因的转录增加,这是通过核视黄酸受体 RARα 的配体依赖性激活引起的。RARα 是存在于 MIR21 基因 5'侧翼区的转录复合物的一部分。该受体结合到映射到转录起始位点上游的两个功能性视黄酸反应元件上。miR-21 的沉默增强了 ATRA 依赖性的生长抑制和衰老,同时逆转了视黄酸提供的细胞迁移抑制。miR-21 的上调导致视黄酸依赖性抑制已建立的靶基因 maspin。在 MCF-7 细胞中敲低和过表达 maspin 表明该蛋白参与 ATRA 诱导的生长抑制,并有助于 ATRA 依赖性抗迁移反应。通过对 MCF-7 和 MDA-MB-231 细胞中 ATRA 差异调节基因的全基因组分析、miR-21 调节基因的预测和功能研究的整合,鉴定了三个新的直接 miR-21 靶基因:促炎细胞因子 IL1B、粘附分子 ICAM-1 和 PLAT,组织型纤溶酶原激活物。提供了 ICAM-1 参与视黄酸依赖性 MCF-7 细胞迁移抑制的证据。